Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise

Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise

Published

on

Alnylam’s revenue cut “may create a near term credibility overhang and could “raise questions on peak sales potential, even if there’s tailwinds in the competitive landscape,” according to Stifel.​ ​Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

AbbVie shares pressured as Q2 I&I beat falls below investor expectations

Published

on

AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.

Continue Reading

Uncategorized

Novo’s IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%

Published

on

Novo Nordisk’s IL-6 inhibitor ziltivekimab failed to reduce the risk of cardiovascular events in the late-stage trial, dashing hopes for an edge in the hyper-competitive cardiometabolic space.

Continue Reading

Uncategorized

Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs

Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.

Read More

Published

on

Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.

Read More

Continue Reading
Advertisement

Trending